Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study

BACKGROUND: Treatment with tamoxifen or chemotherapy reduces the risk of contralateral breast cancer (CBC). However, it is uncertain how long the protection lasts and whether the protective effect is modified by patient, tumor, or treatment characteristics. METHODS: The population-based WECARE Study...

Descripción completa

Detalles Bibliográficos
Autores principales: Langballe, Rikke, Mellemkjær, Lene, Malone, Kathleen E., Lynch, Charles F., John, Esther M., Knight, Julia A., Bernstein, Leslie, Brooks, Jennifer, Andersson, Michael, Reiner, Anne S., Liang, Xiaolin, Woods, Meghan, Concannon, Patrick J., Bernstein, Jonine L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940926/
https://www.ncbi.nlm.nih.gov/pubmed/27400983
http://dx.doi.org/10.1186/s13058-016-0726-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940926/
https://www.ncbi.nlm.nih.gov/pubmed/27400983
http://dx.doi.org/10.1186/s13058-016-0726-0

Ejemplares similares